Giant cell arteritis: A nationwide, population-based cohort study on incidence, diagnostic imaging, and glucocorticoid treatment

2021 ◽  
Vol 51 (2) ◽  
pp. 360-366
Author(s):  
Philip Therkildsen ◽  
Annette de Thurah ◽  
Ib Tønder Hansen ◽  
Mette Nørgaard ◽  
Berit Dalsgaard Nielsen ◽  
...  
2019 ◽  
Vol 47 (9) ◽  
pp. 1385-1391 ◽  
Author(s):  
Niv Ben-Shabat ◽  
Shmuel Tiosano ◽  
Ora Shovman ◽  
Doron Comaneshter ◽  
Yehuda Shoenfeld ◽  
...  

Objective.Studies regarding mortality among patients with giant cell arteritis (GCA) have yielded conflicting results. Thus in this large population-based study we aimed to examine whether GCA is associated with increased mortality, and if so, the effect of age at diagnosis and sex on the association.Methods.We used the medical database of Clalit Health Services for this retrospective cohort study. Followup was from January 1, 2002, and continued until death or end of followup on September 1, 2018. Incident GCA patients were compared with age- and sex-matched controls. Estimated median survival times were calculated using the Kaplan-Meier method. HR for all-cause mortality were obtained by the Cox proportional hazard model, adjusted for sociodemographic variables and cardiovascular risk factors.Results.The study included 7294 patients with GCA and 33,688 controls. The mean age at start of followup was 72.1 ± 9.9 years with 69.2% females. Estimated median survival time was 13.1 years (95% CI 12.6–13.5) in patients with GCA compared with 14.4 years (95% CI 14.1–14.6) in controls (p < 0.001). The multivariate analysis demonstrated increased mortality risk in the first 2 years after diagnosis (HR 1.14, 95% CI 1.04–1.25) and > 10 years after diagnosis (HR 1.14, 95% CI 1.02–1.3). The mortality risk was higher in patients diagnosed at ≤ 70 years of age [HR 1.5 (95% CI 1.14–1.99) 0–2 yrs; HR 1.38 (95% CI 1.1–1.7) > 10 yrs].Conclusion.Patients with GCA have a minor decrease in longterm survival compared to age- and sex-matched controls. The seen difference is due to excess mortality in the first 2 years, and > 10 years after diagnosis. Patients diagnosed ≤ 70 years of age are at greater risk.


Rheumatology ◽  
2010 ◽  
Vol 49 (11) ◽  
pp. 2104-2108 ◽  
Author(s):  
V. S. Schafer ◽  
T. A. Kermani ◽  
C. S. Crowson ◽  
G. G. Hunder ◽  
S. E. Gabriel ◽  
...  

2015 ◽  
Vol 67 (3) ◽  
pp. 396-402 ◽  
Author(s):  
Prabhu D. Udayakumar ◽  
Arun K. Chandran ◽  
Cynthia S. Crowson ◽  
Kenneth J. Warrington ◽  
Eric L. Matteson

PLoS ONE ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e0149579 ◽  
Author(s):  
Alberto Lo Gullo ◽  
Matthew J. Koster ◽  
Cynthia S. Crowson ◽  
Ashima Makol ◽  
Steven R. Ytterberg ◽  
...  

Rheumatology ◽  
2014 ◽  
Vol 53 (suppl 2) ◽  
pp. i14-i14
Author(s):  
P. Deepak Udayakumar ◽  
A. K. Chandran ◽  
C. S. Crowson ◽  
K. J. Warrington ◽  
E. L. Matteson

Rheumatology ◽  
2014 ◽  
Vol 53 (suppl 2) ◽  
pp. i13-i13
Author(s):  
P. Deepak Udayakumar ◽  
A. K. Chandran ◽  
C. S. Crowson ◽  
K. J. Warrington ◽  
E. L. Matteson

Rheumatology ◽  
2014 ◽  
Vol 53 (suppl 2) ◽  
pp. i13-i13
Author(s):  
P. Deepak Udayakumar ◽  
A. K. Chandran ◽  
C. S. Crowson ◽  
K. J. Warrington ◽  
E. L. Matteson

Sign in / Sign up

Export Citation Format

Share Document